Get the app
US › Healthcare

Opus Genetics, Inc. (IRD)

US · Healthcare · Biotechnology

$5.28-2.40%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$755,000
Revenue YoY
-73.8%
Net profit
$-8.1M
EPS
$-0.14
EPS estimate
$-0.15
Net margin
-1,072.6%

EPS came in at -0.14 against a street estimate of -0.15 — a beat of 6.7%.

Key statistics

Market cap
$502.5M
Forward P/E
12.0
P/B
23.82
Book value
$-0.16
EPS (TTM)
$-1.28
52-week high
$7.07
52-week low
$1.35
50-day MA
$3.85
200-day MA
$3.75
Beta
0.58

Analyst view

Analysts rate Opus Genetics, Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $13.00.

Shareholding

Insiders
11.85%
Institutions
69.25%

Largest institutional holders

FundStake
Caligan Partners LP7.30%
Adage Capital Partners Gp LLC7.25%
BIOS CAPITAL MANAGEMENT, LP4.43%
Trails Edge Capital Partners, LP3.30%
Balyasny Asset Management LLC3.27%
Vanguard Capital Management, LLC2.94%
Marshall Wace Asset Management Ltd2.78%
Millennium Management LLC2.77%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Opus Genetics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.